An observational study in Dry AMD and Overactive Bladder, sponsored by University of Naples. Not yet recruiting at 1 site in Italy. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-02-06.
Sponsored by University of Naples · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Urinary Bladder, Overactive with a site in Italy — 3 open to participants now, 3 under way, none of them phase 3. Urinary Bladder, Overactive · Italy.
Among the 30 studies in Urinary Bladder, Overactive with a site in Italy, this one is the only one that started in 2026, is one of 5 observational ones, and was the 30th registered.
861 studies on the registry are indexed under Urinary Bladder, Overactive; 128 are open to participants now.
Browse Urinary Bladder, Overactive studies →3 of the 30 studies in Urinary Bladder, Overactive with a site in Italy are open now. Recruiting first, the newest first:
Stimuli Technology · Sites in Italy, France, United Kingdom
Ages 18+
IRCCS San Raffaele · Sites in Italy
Ages 18+ · Women only
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 75 Urinary Bladder, Overactive studies recruiting now, 45 (60%) set no upper age limit and 16 (21%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 13 · Phase 4 6
First in 2003; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 312 is above the median of 120 across 169 observational studies indexed under Urinary Bladder, Overactive.
Median enrollment 884 across the 24 interventional studies, 312 across the 3 observational. Of the 27 that completed or were terminated, 16 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 30 have an industry lead sponsor. The 10 most frequent:
University of Naples is the lead sponsor of 11 studies on the registry; 2 are open to participants now.
University of Naples has 1 study filed under Urinary Bladder, Overactive — fewer than ten, so there is no comparison to draw.
1 of the studies in Urinary Bladder, Overactive with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07305298University of NaplesMirabegron in Patients With Age-Related Macular Degeneration | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies in Urinary Bladder, Overactive with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if Mirabegron works to treat dry AMD in patients, aged between 50 and 80 years-old, with early or moderate dry AMD and overactive bladder.
The main question it aims to answer is:
Researchers will compare the safety and efficacy of mirabegron versus conventional approach (Solifenacin) to treat dry AMD in patients with dry AMD and overactive bladder.
Participants will:
subjects aged between 50 and 80 years-old with early or moderate dry AMD and overreactive bladder treated with either Mirabegron or Solifenacin
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any medical condition which contraindicates the use of beta-agonists
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Mirabegron will be administered per os at the dose of 50 mg/day for 12 months
Drug: Mirabegron 50mg
Solifenacin will be administered per os at the dose of 5mg/day for 12 months
Drug: Solifenacin 5mg
Mirabegron (50mg/day per os) will be administered in patients with dry AMD and overactive bladder (MMirabegron arm)
Solifenacin (5mg/day per os) will be administered in control group (dry amd and overactive bladder)
Changes in outer retinal morphology using SD-OCT
Outer nuclear layer (ONL) thickness, choroidal thickness (ChT), central macular thickness (CMT) will all be measured in micron
Time frame: "From enrollment to the end of treatment at 12 months
Changes in FAF assessing
changes in FAF measured in micron
Time frame: "From enrollment to the end of treatment at 12 months
mean BCVA
Mean BCVA according to the ETDRS charts
Time frame: From enrollment to the end of treatment at 12 months
Mean macular sensitivity (MS)
Time frame: From enrollment to the end of treatment at 12 months
Safety parameters
blood pressure measured in mmHg
Time frame: From enrollment to the end of treatment at 12 months
Safety parameters
heart frequency in bpm
Time frame: From enrollment to the end of treatment at 12 months
Safety parameters
SpO2 (Peripheral Oxygen Saturation) in % saturation
Time frame: From enrollment to the end of treatment at 12 months
Safety parameters
Respiratory rate in dpm
Time frame: From enrollment to the end of treatment at 12 months
Start is estimated for Apr 2026; primary completion for Dec 2026, 8 months later.
Of 46 non-industry observational studies under Urinary Bladder, Overactive, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's planned 8 months is below that.
Counting every sponsor, half of 59 studies reached it within 32 months; a quarter within 17 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Naples